Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 24, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - March 24, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/24/17 - "Fast Acting Orally Disintegrating Film" in Patent Application Approval Process (USPTO 20170056374)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Lee, Catherine; Wang, Chien-Chiao, filed on November 14, 2016, was made available online on March 9, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to TAHO Pharmaceuticals Ltd.
3/24/17 - AARP: Repealing Obamacare would hurt Hawaii's seniors
AARP, a nonprofit, nonpartisan, social welfare organization, released a scathing assessment of the Republican-proposed health care bill that's facing opposition from not only Democrats but a segment of the GOP in the U.S. House of Representatives. AARP is strongly against the age tax and other aspects of the bill that will give tax breaks to drug c
3/24/17 - Amring Pharmaceuticals Acquired Six ANDAs
By a News Reporter-Staff News Editor at Drug Week Amring Pharmaceuticals Inc., a generic pharmaceutical company, announced that it acquired six ANDAs from Luitpold Pharmaceuticals, Inc. and AlphaForce, L.L.P., a joint venture between Luitpold Pharmaceuticals, Inc. and Alphagen Laboratories Inc. Acquired ANDAs include niche otic and ophthalmic...
3/24/17 - Analyst Activity Wedbush Raises Its Price Target On Ascendis Pharma A/S (NASDAQ:ASND) to
Analyst Ratings For Ascendis Pharma A/S (NASDAQ:ASND) Today, Wedbush raised its price target on Ascendis Pharma A/S (NASDAQ:ASND) to per share. There are 1 hold rating, 2 buy ratings on the stock. The current consensus rating on Ascendis Pharma A/S (NASDAQ:ASND) is Buy (Score: 2.67) with a consensus target price of $30.67 per share, a [?] The pos
3/24/17 - Analyst Activity Wedbush Raises Its Price Target On Ascendis Pharma A/S (NASDAQ:ASND) to $34.00
Analyst Ratings For Ascendis Pharma A/S (NASDAQ:ASND) Today, Wedbush raised its price target on Ascendis Pharma A/S (NASDAQ:ASND) to $34.00 per share. There are 1 hold rating, 2 buy ratings on the stock. The current consensus rating on Ascendis Pharma A/S (NASDAQ:ASND) is Buy (Score: 2.67) with a consensus target price of $30.67 per share, [?] Th
3/24/17 - Arbutus Biopharma Corp. Files SEC Form 8-K, Current Report (Mar. 6, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on March 6, 2017. The SEC file number is 0001171843-17-001299.. A U.S. Securities and Exchange Commission filing is a formal
3/24/17 - AveXis Reports Topline Results from Phase 1 Trial of SMA Type 1 Gene Therapy [Syrian Arab News Agency]
AveXis, a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, reported topline results from the Phase 1 trial of AVXS-101 in spinal muscular atrophy Type 1. The completion of our Phase 1 clinical study of AVXS-101, the first ever gene therapy studied for the.
3/24/17 - Avita Medical to Present at Needham Healthcare Conference
VALENCIA, Calif.& PERTH, Australia& LONDON Avita Medical Limited, a regenerative medicine company focused on the treatment of wounds and skin defects, today announced that Adam Kelliher, Avita s Chief Executive Officer will present at the 16th Annual Needham Healthcare Conference on 4 April 2017. The presentation will take place at 9:20am ET
3/24/17 - Beat market volatility with these stock option trade ideas for Citigroup, Exelixis, Gilead Sciences, Tesla Motors, and US Oil Fund!
By a News Reporter-Staff News Editor at Drug Week- InvestorsObserver issues critical PriceWatch Alerts for C, EXEL, GILD, TSLA, and USO. Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. Tesla Inc, formerly Tesla Motors Inc designs, develops,.
3/24/17 - Bharat Book Bureau: Global Transdermal Patch Market
"Global Transdermal Patch Market& Clinical Pipeline Outlook 2022" report discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market. Report highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies.
3/24/17 - Bharat Book Bureau: Infectious Disease Drugs: The Chinese Market
The Chinese infectious disease drug market is big, fast-growing and dominated by brands from outside China. This market is very important for pharmaceutical companies in North America, Europe and other developed regions that look for strong growth and high profits in the following decade. The goal of this study is to help readers achieve a comprehe
3/24/17 - Bioinformatics Market Is Expected To Growing At An Estimated CAGR of 21.2% From 2014 To 2020: Grand View Research, Inc.
According to new report by Grand View Research, The Global bioinformatics market size was valued at USD 3.51 billion in 2013. Growing clinical development of biopharmaceutical and increasing need for three dimensional drug designing technology are expected to drive the market. The global bioinformatics market is expected to reach USD 13.47 billion
3/24/17 - Biosimilar of costly inflammatory bowel disease therapy found safe and effective
By a News Reporter-Staff News Editor at Drug Week Treatment of Crohn's disease and ulcerative colitis has been greatly improved by the introduction of biologic therapies such as infliximab, but at considerable cost. CT-P13 has been recently approved in the United States, the European Union, Australia, Canada, Japan, and many other countries.
3/24/17 - Biotech Stocks Under Scanner BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
This Friday, Stock-Callers.com has initiated reports coverage on the following Biotechnology equities: BioDelivery Sciences International Inc., Sage Therapeutics Inc., Benitec Biopharma Ltd, and OncoGenex Pharmaceuticals Inc.. On Thursday, shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. ended the session...
3/24/17 - Biothera Pharmaceuticals Phase 2 Study of Imprime PGG Combination Therapy inNon-Small Cell Lung Cancer Patients Published in Investigational New Drugs
Biothera Pharmaceuticals, Inc. today announced peer-reviewed publication of results of a randomized Phase 2 clinical study of the Company s cancer immunotherapy Imprime PGG in combination with Erbitux and chemotherapy in metastatic non-small cell lung cancer patients. Completed by Biothera in 2013, the study was part of an early series of c
3/24/17 - Cell Therapy Manufacturing Market (2017-2027): Near-Term Demand Driven by Clincial Candidates - Research and Markets
Research and Markets has announced the addition of the "Cell Therapy Manufacturing Market, 2017-2027" report to their offering. The Cell Therapy Manufacturing Market, 2017-2027 report provides an extensive study of the rapidly growing market of cell therapy manufacturing and focuses both on contract manufacturers and cell therapy developers with...
3/24/17 - Chiesi USA, Inc. Earns Triangle Business Journal's Corporate Philanthropy Award
Chiesi USA, a Cary- based specialty pharmaceutical company, was recognized this week by the Triangle Business Journal for its corporate philanthropy efforts. In the past 12- months, Chiesi USA awarded more than $550,000 in support of patients within its therapeutic areas and select local charities. The four key goals of the program are to impact Ch
3/24/17 - China looks to streamline drug approvals [T-break Tech (Middle East)]
At present, new drugs are often launched in China years after they are available in other countries. China is the worlds second-largest drug market but one where foreign firms have struggled with regulations on new products, according to the U.S. International Trade Administration. In addition, foreign manufacturers would not have to undertake...
3/24/17 - CHMP provides positive opinion for EU label update for Novo Nordisk's Tresiba based on data from SWITCH trials
Bagsvrd, Denmark, 24 March 2017- Novo Nordisk today announced that the Committee for Medicinal Products for Human Use, under the European Medicines Agency, has issued a positive opinion, recommending an update of the label for Tresiba to include data from the SWITCH 1 and 2 clinical trials. "Following the submission of the application to the EMA
3/24/17 - CorMedix Inc. Makes NYSE MKT Section 610(b) Public Announcement
BEDMINSTER, NJ/ ACCESSWIRE/ March 23, 2017/ CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that, as previously disclosed in its Annual Report on Form 10- K for the year ended December 31, 2016, filed Ma
3/24/17 - Cti Biopharma Corp. Files SEC Form 10-K, Annual Report [Section 13 And 15(D), Not S-k Item 405] (Mar. 2, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Cti Biopharma Corp. was posted on March 2, 2017. The SEC file number is 0000891293-17-000030.. A U.S. Securities and Exchange Commission filing is a formal docu
3/24/17 - Cti Biopharma Corp. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Mar. 6, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Cti Biopharma Corp. was posted on March 6, 2017. The SEC file number is 0000899243-17-006599.. A U.S. Securities and Exchange Commission filing is a formal docu
3/24/17 - Cti Biopharma Corp. Files SEC Form 8-K, Current Report (Mar. 2, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Cti Biopharma Corp. was posted on March 2, 2017. The SEC file number is 0000891293-17-000027.. A U.S. Securities and Exchange Commission filing is a formal docu
3/24/17 - CURE Pharmaceutical Welcomes Researcher and Innovator in Pediatric Medicine Michael Neely to Advisory Board [T-break Tech (Middle East)]
-CURE Pharmaceutical, or, a leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities, today announces the appointment of Michael Neely, MD, 47, to its Advisory Board. Michael Neely, MD, currently serves as acting chief of infectious
3/24/17 - EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer [Tehran Times (Iran)]
-Advaxis, Inc., a biotechnology company developing cancer immunotherapies, today announced the European Medicines Agency issued an advanced therapy medicinal product certificate for manufacturing quality and non-clinical data. Advaxis is now positioned to file the complete MAA in the second half of 2017.. EMAs issuance of this certification is a ma
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415